pioglitazone has been researched along with oxidopamine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bordet, R; Devos, D; Laloux, C; Lecointe, C; Petrault, M | 1 |
| Bassani, TB; Bonato, JM; de Oliveira, RMW; Milani, H; Vital, MABF | 1 |
| Andreatini, R; Bassani, TB; Cóppola-Segovia, V; Machado, MMF; Moura, ELR; Vital, MABF; Zanata, SM | 1 |
3 other study(ies) available for pioglitazone and oxidopamine
| Article | Year |
|---|---|
Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Male; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Substantia Nigra; Thiazolidinediones; Visual Cortex | 2012 |
Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Male; Mortality; Neurogenesis; Oxidopamine; Parkinson Disease, Secondary; Pioglitazone; Random Allocation; Rats; Thiazolidinediones | 2018 |
PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Male; Microglia; Motor Activity; Neuroprotective Agents; NF-kappa B; Oxidopamine; Parkinson Disease; Pioglitazone; PPAR gamma; Rats, Wistar; Substantia Nigra | 2019 |